Table 3.
Association Between BRAF V600E Mutation and Clinicopathological Features of PTC Patients with Maximum Tumor Diameter >1.0cm
| Clinicopathological Features | PTC with >1 cm (n=270) | BRAF | P value | |
|---|---|---|---|---|
| Wild Type (n=57) | V600E (n=213) | |||
| Gender | ||||
| Male | 46(17.0%) | 10(17.5%) | 36(16.9%) | 1.000 |
| Female | 224(83.0%) | 47(82.5%) | 177(83.1%) | |
| Age | ||||
| <55 | 215(79.6%) | 48(84.2%) | 167(78.4%) | 0.363 |
| ≥55 | 55(20.4%) | 9(15.8%) | 46(21.6%) | |
| History of smoking | ||||
| Never | 267(98.9%) | 56(98.2%) | 211(99.1%) | 0.511 |
| Ever or Current | 3(1.1%) | 1(1.8%) | 2(0.9%) | |
| History of alcohol consumption | ||||
| Never | 267(98.9%) | 57(100.0%) | 210(98.6%) | 1.000 |
| Ever or Current | 3(1.1%) | 0(0) | 3(1.4%) | |
| Cancer site | ||||
| Unilateral | 210(77.8%) | 50(87.7%) | 160(75.1%) | 0.048 |
| Bilateral | 60(22.2%) | 7(12.3%) | 53(24.9%) | |
| Disease stage | ||||
| I–II | 236(87.4%) | 50(87.7%) | 186(87.3%) | 1.000 |
| III–IV | 34(12.6%) | 7(12.3%) | 27(12.7%) | |
| T-stage | ||||
| T1-T2 | 177(65.6%) | 41(71.9%) | 136(63.8%) | 0.276 |
| T3-T4 | 93(34.4%) | 16(28.1%) | 77(36.2%) | |
| N-stage | ||||
| N0 | 89(33.0%) | 21(36.8%) | 68(31.9%) | 0.527 |
| N1 | 181(67.0%) | 36(63.2%) | 145(68.1%) | |
| Hashimoto’s thyroiditis | ||||
| No | 233(86.3%) | 50(87.7%) | 183(85.9%) | 0.831 |
| Yes | 37(13.7%) | 7(12.3%) | 30(14.1%) | |
| Calcification | ||||
| No | 163(60.4%) | 31(54.4%) | 132(62.0%) | 0.360 |
| Yes | 107(39.6%) | 26(45.6%) | 81(38.0%) | |
| Risk of recurrence | ||||
| Low | 68(25.2%) | 20(35.1%) | 48(22.5%) | 0.120 |
| Medium | 130(48.1%) | 22(38.6%) | 108(50.7%) | |
| High | 72(26.7%) | 15(26.3%) | 57(26.8%) | |